As interest in personalized medicine increases, physicians and researchers require even more data about their patients to recommend the best treatment options. However, most clinical trials – studies that determine the efficacy and safety of new treatments and are key to getting these treatments to patients – are not currently designed with personalized medicine in mind. A $10.4 million grant from the National Cancer Institute will help researchers from NC State, UNC-Chapel Hill and Duke University develop new statistical methods that can be used to both design clinical trials for cancer treatments and analyze the resulting data. These new trials, designed to incorporate a large variety of factors, will help physicians ensure the best outcomes for patients based on their individual characteristics.
The new funding represents a five-year extension of the original $12.5 million grant, which was awarded in 2010.
“Currently, most clinical trials offer a randomized snapshot of one moment in time,” says Marie Davidian, William Neal Reynolds Professor of Statistics at NC State and a principal investigator on the project. “These trials can tell you whether treatment A or B is more effective, on average.
Read the full article on NC State News.